US-based Tear Film focusses on developing medical products to treat various eye disorders and its portfolio includes a handheld and portable therapeutic device called iLux.
iLux is used for the treatment of meibomian gland dysfunction (MGD) that leads to dry eye.
Eye care professionals can use the device to directly target blocked meibomian glands and deliver in-office therapy.
iLux works by applying light-based heat and compression via disposable silicone pads in order to soften blockages of the meibomian gland orifices.
It enables the practitioner to view the eyelid margin and apply manually-controlled compression based on the patients’ individual requirements.
Novartis said that the Tear Film acquisition boosts Alcon’s ocular health products portfolio, which includes treatments for the temporary relief of dry eye symptoms.
Alcon Global Vision Care Franchise president and general manager Andy Pawson said: “With the acquisition of Tear Film, we’re excited to bring this latest innovation to treat the millions of people around the world who suffer from dry eye.
“Alcon remains committed to improving the lives of patients around the world through innovative technologies like the iLux device to address significant unmet needs in eye care.”
Tear Film commercially launched the iLux device in May after obtaining the US Food and Drug Administration (FDA) 510(k) clearance last December.
Tear Film CEO Rob Thornhill said: “Since launching the iLux device earlier this year, we’ve seen an enthusiastic response from eye care professionals who have already begun to incorporate it as an advanced treatment option for patients suffering from Meibomian Gland Dysfunction.
“Now, as part of Alcon, we’re eager to bring this technology to even more offices throughout the world.”
Alcon noted that it will launch iLux in new markets next year.
The device is currently only available in the US and Canada.